Kura Oncology (KURA) Revenue & Revenue Breakdown
Kura Oncology Revenue Highlights
Latest Revenue (Y)
$53.88M
Latest Revenue (Q)
$14.11M
Kura Oncology Revenue by Period
Kura Oncology Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $53.88M | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2008-12-31 | - | - |
Kura Oncology generated $53.88M in revenue during NA 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Kura Oncology Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-03-31 | $14.11M | -73.82% |
| 2024-12-31 | $53.88M | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $1.27M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $2.44M | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | - |
Kura Oncology generated $14.11M in revenue during Q1 2025, up -73.82% compared to the previous quarter, and up 1110.87% compared to the same period a year ago.
Kura Oncology Revenue Breakdown
Kura Oncology Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Jun 25 |
|---|---|
| Operating Segments | $15.29M |
Latest
Kura Oncology's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Operating Segments (100.00%).
Kura Oncology Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| FTRE | Fortrea | $2.70B | $710.30M |
| MRVI | Maravai LifeSciences | $259.19M | $47.40M |
| DNA | Ginkgo Bioworks | $227.04M | $48.32M |
| VALN | Valneva SE | $153.70M | $32.75M |
| URGN | UroGen Pharma | $90.40M | $20.25M |
| VIR | Vir Bio | $74.20M | $1.21M |
| PHAT | Phathom Pharmaceuticals | $55.25M | $39.50M |
| KURA | Kura Oncology | $53.88M | $14.11M |
| EYPT | EyePoint Pharmaceuticals | $43.27M | $5.33M |
| XNCR | Xencor | - | $32.73M |
| AVBP | ArriVent BioPharma | - | - |